- Home
- CIVB vs RAPT Comparison
CIVB vs RAPT Comparison
Compare CIVB & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIVB
- RAPT
- Stock Information
- Founded
- CIVB 1884
- RAPT 2015
- Country
- CIVB United States
- RAPT United States
- Employees
- CIVB N/A
- RAPT N/A
- Industry
- CIVB Major Banks
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- CIVB Finance
- RAPT Health Care
- Exchange
- CIVB Nasdaq
- RAPT Nasdaq
- Market Cap
- CIVB 422.4M
- RAPT 498.4M
- IPO Year
- CIVB N/A
- RAPT 2019
- Fundamental
- Price
- CIVB $21.89
- RAPT $28.83
- Analyst Decision
- CIVB Buy
- RAPT Strong Buy
- Analyst Count
- CIVB 5
- RAPT 9
- Target Price
- CIVB $25.40
- RAPT $57.00
- AVG Volume (30 Days)
- CIVB 78.6K
- RAPT 778.5K
- Earning Date
- CIVB 10-23-2025
- RAPT 11-06-2025
- Dividend Yield
- CIVB 3.10%
- RAPT N/A
- EPS Growth
- CIVB 33.31
- RAPT N/A
- EPS
- CIVB 2.66
- RAPT N/A
- Revenue
- CIVB $163,095,000.00
- RAPT N/A
- Revenue This Year
- CIVB $18.06
- RAPT N/A
- Revenue Next Year
- CIVB $10.83
- RAPT N/A
- P/E Ratio
- CIVB $8.23
- RAPT N/A
- Revenue Growth
- CIVB 11.28
- RAPT N/A
- 52 Week Low
- CIVB $17.47
- RAPT $5.67
- 52 Week High
- CIVB $25.59
- RAPT $42.39
- Technical
- Relative Strength Index (RSI)
- CIVB 58.77
- RAPT 53.26
- Support Level
- CIVB $21.19
- RAPT $27.76
- Resistance Level
- CIVB $22.19
- RAPT $29.90
- Average True Range (ATR)
- CIVB 0.41
- RAPT 1.66
- MACD
- CIVB 0.00
- RAPT -0.46
- Stochastic Oscillator
- CIVB 73.00
- RAPT 41.72
About CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.